Arcadia Biosciences, Inc. RKDA
Nasdaq · XNAS · stock · Crude Petroleum & Natural Gas
Chart by TradingView
2/9
Piotroski F — financial health
-136.5
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $4.9M | -$2.3M | — | -$4.7M | $4.1M |
| 2024 | $5.0M | -$7.0M | — | -$9.6M | $6.2M |
| 2023 | $4.5M | -$14.0M | — | -$15.3M | $12.7M |
| 2022 | $7.4M | -$15.4M | — | -$14.0M | $20.9M |
| 2021 | $6.8M | -$14.7M | — | -$26.9M | $31.2M |
| 2020 | $8.0M | -$4.7M | — | -$32.6M | $28.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Kawakami Mark | Chief Financial Officer | 2025-02-03 | Buy | 700 | $2.49 |
| Schaefer Thomas J. | Chief Executive Officer | 2025-02-03 | Buy | 700 | $2.49 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -136.5 (distress)
- Working capital / assets 0.656
- Retained earnings / assets -42.96
- EBIT / assets -0.382
- Equity / liabilities 1.721
Source: SEC EDGAR filings · CIK 0001469443 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.